US › Healthcare

Akari Therapeutics PLC (AKTX)

US · Healthcare · Biotechnology

$7.79+5.84%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Revenue YoY
-100.0%
Net profit
$-14.5M
Profit YoY
-290.1%
EPS
$-9.72
EPS estimate
$-0.66

EPS came in at -9.72 against a street estimate of -0.66 — a miss of 1372.9%.

Key statistics

Market cap
$12.9M
P/E
0.0
Forward P/E
0.0
P/B
0.95
Book value
$12.56
EPS (TTM)
$0.00
52-week high
$49.60
52-week low
$3.02
50-day MA
$12.16
200-day MA
$12.39
Beta
1.39

Analyst view

Analysts rate Akari Therapeutics PLC a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $28.39.

Shareholding

Insiders
16.80%
Institutions
8.97%

Largest institutional holders

FundStake
Armistice Capital, LLC0.06%
Cresset Asset Management, LLC0.03%
IFP Advisors, LLC0.00%
SBI Securities Co Ltd0.00%
Morgan Stanley - Brokerage Accounts0.00%
Truvestments Capital LLC0.00%
Palo Alto Investors, LLC0.00%
CWA Asset Management Group, LLC0.00%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Akari Therapeutics PLC — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.